Literatur
-
1
Anderson J L, Karagounis L A, Califf R M.
Metaanalysis of five reported
studies on the relation of early coronary patency grades with mortality
and outcomes after acute myocardial infarction.
Am J Cardiol.
1996;
78
1-8
-
2
Armstrong P W, Granger C, Van de Werf F.
Bolus
fibrinolysis. Risk, benefit, and opportunities.
Circulation.
2001;
103
1171-1173
-
3
Arntz H R, Tebbe U, Schuster H P, Sauer G, Meyer J.
Leitlinien
zur Diagnostik und Therapie des akuten Herzinfarkts in der Prähospitalphase.
Z
Kardiol.
2000;
89
364-372
-
4
ASSENT-2 Investigators .
Single-bolus
tenecteplase compared with front-loaded alteplase in acute myocardial
infarction. The ASSENT-2 double blind randomized trial.
Lancet.
1999;
354
716-722
-
5
ASSENT-3 Investigators .
Efficacy
and safety of tenecteplase in combination with enoxaparin, abciximab,
or unfractionated heparin: the ASSENT-3 randomised trial in acute
myocardial infarction.
Lancet.
2001;
338
605-613
-
6
Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. the ISIS-2 Collaborative Group.
I .
SIS-2: 10-year survival among patients with suspected
acute myocardial infarction in randomised comparison of intravenous
streptokinase, oral aspirin, both, or neither.
BJM.
1998;
316
1337-1343
-
7
Bode C, Smalling R W, Berg G, Burnett C, Lorch G, Kalbfleisch J M, Chernoff R, Christie L G, Feldman R L, Seals A A, Weaver W D. for the RAPID-II
Investigators .
Randomized comparison of coronary thrombolysis
avchieved with double-bolus reteplase (recombinant plasminogen activator)
and front-loaded, accelerated alteplase (recombinant tissue plasminogen
activator) in patients with acute myocardial infarction.
Circulation.
1996;
94
891-898
-
8
Cannon C P, McCabe C H, Diver D J. et al .
Comparison of front-loaded
recombinant tissue-type plasminogen activator, anistreplase and
combination thrombolytic therapy for acute myocardial infarction.
Results of the TIMI 4 trial.
J Am Coll Cardiol.
1994;
24
1602-1610
-
9
Cannon C P, Gibson M, McCabe C H. et al .
TNK-tissue plasminogen activator compüared
with front-loaded alteplase in acute myocardial infarction. Results
of the TIMI 10B trial.
Circulation.
1998;
98
2805-2814
-
10
Cannon C.
Thrombolytic
medication errors: benefits of bolus thrombolytic agents.
Am
J Cardiol.
2000;
85
17C-22C
-
11
Cannon C P, Gibson M, Murphy S A, Van de Werf F, McCabe C.
Weight-based dosing
of thrombolysis. How well do we estimate weigh? How often would this
translate into errors with administration of thrombolytic drugs?
A comparison of single-bolus TNK with t-PA in TIMI 10B.
J
Am Coll Cardiol.
2001;
37
323A
(Suppl A)
-
12
Coulter S A, McCabe C H, Giugliano R P, Cutler S S, Charlesworth A, Chew P, Cannon C P.
Dosing errors and outcomes in patients receiving
single bolus compared with bolus + infusion regimens thrombolytic
regimens: an InTIME-2 study.
Circulation.
1999;
100
(Suppl I)
I-791
-
13
Fibrinolytic Therapy Trialists’ (FTT)
Collaborative Group .
Indications for fibrinolytic therapy
in suspected acute myocardial infarction: collaborative overview
of early mortality and major morbidity results from all randomised
trials of more than 1000 patients.
Lancet.
1994;
343
311-322
-
14
Franzosi M G, Santoro E, De Vita C, Geraci E, Lotto A, Maggioni F, Rovelli F, Santoro L, Tavazzi L, Tognoni G. on behalf of the GISSI Investigators .
Ten-year
follow-up of the first megatrial testing thrombolytic therapy in
patients with acute myocardial infarction.
Circulation.
1998;
98
2659-2665
-
15
Giugliano R P, Antman E M, McCabe C H. et al .
InTIME-2b: omission of heparin bolus
lowers rate of intracranial hemorrhage with lanoteplase.
J
Am Coll Cardiol.
2000;
35
(Suppl )
407A
-
16
Giugliano R P, McCabe C H, Antaman E M. et al .
Lower-dose heparin with
fibrinolysis is associated with lower rates of intracranial hemorrhage.
Am Heart
J.
2001;
141
742-750
-
17
Granger C B, van de Werf F, Armstrong P W. et al .
Caution needed in interpreting
the impact of dosing errors: a case study from ASSENT 2.
Circulation.
2000;
102
(Suppl II)
II-590
-
18
Gurwitz J H, Gore J M, Goldberg R J. et al .
Risk for intracranial hemorrhage
after tissue plasminogen activator treatment for acute myocardial
infarction: participants in the NRMI 2.
Ann intern Med.
1998;
129
597-604
-
19
InTIME-2 Investigators .
Intravenous
NPA for the treatment of infarcting myocardium early: InTIME-2,
a double-blind comparison of single-bolus lanoteplase versus accelerated
alteplase for the treatment of patients with acute myocardial infarction.
Eur
Heart J.
2000;
21
2005-2013
-
20
ISIS 3 Collaborative Group .
ISIS-3:
a randomised comparison of streptokinase vs tissue plasminogen activator
vs anistreplase and of aspirin plus heparin vs aspirin alone among
41 299 cases of suspected acute myocardial infarction.
Lancet.
1992;
339
753-770
-
21
Mehta S R, Eikelboom J W, Yusuf S.
Risk
of intracranial hemorrhage with bolus versus infusion thrombolytic
therapy: a meta-analysis.
Lancet.
2000;
356
449-454
-
22
Neuhaus K L, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U.
Improved thrombolysis
with a modified dose regimen of recombinant tissue-type plasminogen
activator.
J Am Coll Cardiol.
1989;
14
1566-1569
-
23
Neuhaus K L, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Mäurer W, Limbourg P, Merx W, Haerten K.
Improved thrombolysis
in acute myocardial infarction with front-loaded administration
of alteplase: results of the rt-PA-APSAC Patency Study (TAPS).
J
Am Coll Cardiol.
1992;
19
885-891
-
24
Seyedroudbari A, Kessler E R, Mooss A N, Wundeman R L, Bala M, Hilleman D E.
Time
to treatment and cost of thrombolysis: a multicenter comparison of
tPA and rPA.
J Thromb Thrombolysis.
2000;
9
303-308
-
25
The European Myocardial Infarction
Project Group .
Prehospital thrombolytic therapy in
patients with suspected myocardial infarction.
N Engl
J Med.
1993;
329
383-389
-
26
The GUSTO Angiographic Investigators .
The
effects of tissue plasminogen activator, streptokinase, or both
on coronary artery patency, ventricular function, and survival after
acute myocardial infarction.
N Engl J Med.
1993;
329
1615-1620
-
27
The GUSTO III Investigators .
A
comparison of reteplase with alteplase for acute myocardial infarction.
N
Engl J Med.
1997;
337
1118-1123
-
28 Touboul P. CAPTIM
Study. Vortrag in der Hotline Session I beim ESC-Kongress,
Stockholm 2.9.01
-
29
Vogt A, von Essen R, Tebbe U, Feuerer W, Appel K F, Neuhaus K L.
Impact of early
perfusion status of the infarct-related artery on short-term mortality after
thrombolysis for acute myocardial infarction: retrospective analysis of
four German multicenter studies.
J Am Coll Cardiol.
1993;
21
1391-1395
-
30
White H D, Van de Werf F JJ.
Thrombolysis
for acute myocardial infarction.
Circulation.
1998;
97
1632-1646
-
31 Zeymer U, Neuhaus K L. New Thrombolytic
agents. Humana Press, Totowa, USA In:
C.P. Cannon (Editor): Management of Acute Coronary Syndromes 1998: 243-265
Priv.-Doz. Dr. Uwe Zeymer
Klinikum Ludwigshafen, Medizinische Klinik
B
Bremserstraße 79
67063 Ludwigshafen
Phone: 0621/5030
Fax: 0621/5034002
Email: Uwe.Zeymer@t-online.de
